Alkermes (ALKS)

Company Description

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

 

COMPANY ADDRESS
852 Winter Street
Waltham, MA 02451
United States

COMPANY PHONE
781-609-6000

COMPANY WEBSITE


Get BioInvest's perspective on Alkermes' CEO

Latest Company News

Trading Options: Alkermes plc (NASDAQ:ALKS) : Using Covered Calls to ... CML News - 4 hours ago While covered calls are one of the most commonly used option strategies, it turns out we need to be clever in how we treat earnings in order to maximize the strategy in Alkermes plc (NASDAQ:ALKS) . Even further, if we don't do this analysis, we can ... [...]
Fri, Apr 28, 2017 2:03:00 AM, Continue reading at the source
Alkermes plc Reports First Quarter 2017 Financial Results Yahoo Finance - 19 hours ago Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. Alkermes Plc (NASDAQ:ALKS) reported earnings of ($0.18) per share missing ... - Market Exclusive Alkermes Plc (ALKS) Announces Earnings Results - The Cerbat Gem [...]
Thu, Apr 27, 2017 11:03:00 AM, Continue reading at the source
FY2018 Earnings Estimate for Alkermes Plc (ALKS) Issued By Leerink Swann The Cerbat Gem - Apr 26, 2017 Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) - Equities research analysts at Leerink Swann dropped their FY2018 earnings per share estimates for shares of Alkermes Plc in a research note issued on Thursday, Zacks Investment Research reports. Analyst Activity – Morgan Stanley Reiterates Equal Weight on Alkermes Plc ... - Market Exclusive EPS for Alkermes Plc (ALKS) Expected At $-0.24; New Mountain Vantage Advisers ... - HuronReport [...]
Wed, Apr 26, 2017 3:56:00 AM, Continue reading at the source
Manitowoc Company (MTW) Reaches $6.18 After 4.00% Up Move; Alkermes PLC (ALKS ... HuronReport - Apr 25, 2017 Alkermes plc is a biopharmaceutical company. The company has market cap of $8.75 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in ... [...]
Tue, Apr 25, 2017 8:48:00 PM, Continue reading at the source
Alkermes plc (ALKS) LT Estimates Cut At Morgan Stanley Citing Ampyra Patent ... StreetInsider.com - Apr 24, 2017 Morgan Stanley maintains Equalweight on Alkermes (NASDAQ: ALKS) price target of $62.00. Analyst David Risinger assumes Ampyra generics could hit the market in 2018 as opposed to prior expectations of 2027. [...]
Mon, Apr 24, 2017 11:15:00 AM, Continue reading at the source
Alkermes plc (ALKS) to Present Data on Two-Month Dosing Option of ARISTADA at ... StreetInsider.com - Mar 20, 2017 Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress ... [...]
Mon, Mar 20, 2017 10:52:00 AM, Continue reading at the source
Investors Are Missing An Opportunity With Alkermes Seeking Alpha - Feb 27, 2017 We remain bullish on Alkermes (NASDAQ: ALKS) because of their substantial and growing revenue and their healthy pipeline of valuable assets. [...]
Mon, Feb 27, 2017 7:52:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 15, 2017 Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today. Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and ... - Business Wire (press release) [...]
Wed, Feb 15, 2017 6:10:00 PM, Continue reading at the source
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward Motley Fool - Nov 7, 2016 Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline. [...]
Mon, Nov 07, 2016 7:42:00 PM, Continue reading at the source
Why Alkermes PLC Skyrocketed Today Motley Fool - Oct 21, 2016 Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo. Analysts Change Price Targets for Two Biotech Stocks: Alkermes Plc (ALKS ... - Smarter Analyst Alkermes Surge by a Record 47% on Depression Pill Trial Success - Bloomberg [...]
Fri, Oct 21, 2016 5:26:00 PM, Continue reading at the source